A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)
| Autor: | Gary S. Marshall, Victoria Abbing-Karahagopian, Helen S. Marshall, Silvia Cenci, James H. Conway, Emilia Occhipinti, Rafik Bekkat-Berkani, Angelika Banzhoff, Woo-Yun Sohn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Expert Review of Vaccines, Vol 22, Iss 1, Pp 530-544 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1476-0584 1744-8395 14760584 |
| DOI: | 10.1080/14760584.2023.2222015 |
| Popis: | Introduction Neisseria meningitidis causes invasive meningococcal disease and, globally, significant morbidity, with serogroup B (MenB) being the most common cause of endemic disease and outbreaks in several regions. Extensive use of the four-component serogroup B meningococcal vaccine (4CMenB; Bexsero, GSK) and its inclusion in immunization programs in several countries have generated substantial safety data during the 9 years since its first authorization in 2013. Areas covered 4CMenB safety data from clinical trials and post-marketing surveillance studies (2011 to 2022), and spontaneously reported adverse events of medical interest from the GSK global safety database. We discuss these safety findings in relation to the benefit of 4CMenB vaccination and implications for further enhancing vaccine confidence. Expert opinion 4CMenB has been consistently well tolerated across clinical trials and post-licensure surveillance studies, despite a higher incidence of fever reported in infants than with other pediatric vaccines. Surveillance data have not identified any significant safety issues, consistent with an acceptable safety profile of 4CMenB. These findings highlight the need to balance the risk of relatively common, transient, post-immunization fever with the benefit of affording protection that reduces the risk of uncommon but potentially fatal meningococcal infection. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|